Send to

Choose Destination
Diabetes Res Clin Pract. 2012 Oct;98(1):119-24. doi: 10.1016/j.diabres.2012.04.017. Epub 2012 May 14.

Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.

Author information

Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Greece.



In addition to sulfonylurea-induced severe hypoglycemia, which however is not common in T2DM patients treated solely with oral hypoglycemic drugs, mild hypoglycemia is a frequent adverse event affecting many patients treated with oral hypoglycemic drugs and has a serious impact in patient adherence to therapy and everyday clinical practice. The aim of the present study was to investigate the possible association of KCNJ11 E23K polymorphism with incidence of sulfonylurea-induced mild hypoglycemic events.


176 T2DM patients receiving sulfonylurea were included in the study, including 92 that had experienced drug-associated hypoglycemia and 84 that had never experienced hypoglycemia while on sulfonylurea treatment. KCNJ11 E23K polymorphism was detected by use of PCR-RFLP method.


Frequencies of KCNJ11 E23K genotypes and alleles were not different between hypoglycemic and non-hypoglycemic T2DM patients (p=0.35 and p=0.47, respectively). In logistic regression analysis before and after adjustment for other factors known to affect this condition (age, body mass index, sulfonylurea mean daily dose, duration of T2DM, renal function and CYP2C9 genotype) KCNJ11 E23K polymorphism did not affect hypoglycemia risk.


KCNJ11 E23K polymorphism is not associated with increased risk of mild hypoglycemia in sulfonylurea-treated T2DM patients.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center